Literature DB >> 19752427

The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin epidemiologic study of diabetic retinopathy.

Barbara E K Klein1, Michael D Knudtson, Michael Y Tsai, Ronald Klein.   

Abstract

OBJECTIVE: To determine the relation of glycemia, blood pressure, and serum total cholesterol level as systemic markers of inflammation and endothelial dysfunction to the prevalence and incidence of diabetic retinal outcomes in persons with long-duration type 1 diabetes mellitus.
METHODS: Longitudinal population-based study of persons with type 1 diabetes mellitus who received care for their diabetes in south central Wisconsin from July 1, 1979, to June 30, 1980. Data for this investigation were obtained from the 1990-1992 through the 2005-2007 follow-up examinations. Main outcome measures included the severity of diabetic retinopathy (DR) and macular edema (ME).
RESULTS: In the 1990-1992 prevalence data, soluble vascular cell adhesion molecule, tumor necrosis factor, and homocysteine levels were associated with increased odds of more severe DR (odds ratios [highest vs lowest quartile], 3.95 [95% confidence interval, 1.66-9.39], 5.46 [2.38-12.52], and 7.46 [2.91-19.16], respectively) in those with kidney disease while controlling for relevant confounders. Similar odds were found for proliferative DR. Only total homocysteine level was associated with increased odds of ME (3.80 [95% confidence interval, 1.91-7.54]), irrespective of kidney disease. None of the markers were associated with incidence of proliferative DR, ME, or progression of DR 15 years later.
CONCLUSIONS: A limited number of markers are associated with increased odds of prevalent retinal outcomes in persons with type 1 diabetes mellitus and kidney disease. Only homocysteine level is associated with ME in those with and without kidney disease. In the absence of kidney disease, the markers do not add to the more conventional descriptors and predictors of DR in persons with type 1 diabetes mellitus. This may reflect the close association of DR and kidney disease in diabetic persons.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19752427      PMCID: PMC2746055          DOI: 10.1001/archophthalmol.2009.172

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  59 in total

1.  Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy.

Authors:  Ling Zheng; Scott J Howell; Denise A Hatala; Kun Huang; Timothy S Kern
Journal:  Diabetes       Date:  2007-02       Impact factor: 9.461

2.  Plasma homocysteine and microvascular complications in type 1 diabetes.

Authors:  O Vaccaro; A F Perna; F P Mancini; C Iovine; V Cuomo; M Sacco; A Tufano; A A Rivellese; D Ingrosso; G Riccardi
Journal:  Nutr Metab Cardiovasc Dis       Date:  2000-12       Impact factor: 4.222

3.  A major role for VCAM-1, but not ICAM-1, in early atherosclerosis.

Authors:  M I Cybulsky; K Iiyama; H Li; S Zhu; M Chen; M Iiyama; V Davis; J C Gutierrez-Ramos; P W Connelly; D S Milstone
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

4.  Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability.

Authors:  D Fukumura; T Gohongi; A Kadambi; Y Izumi; J Ang; C O Yun; D G Buerk; P L Huang; R K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

5.  Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy.

Authors:  T Yuuki; T Kanda; Y Kimura; N Kotajima; J Tamura; I Kobayashi; S Kishi
Journal:  J Diabetes Complications       Date:  2001 Sep-Oct       Impact factor: 2.852

6.  Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn study.

Authors:  E K Hoogeveen; P J Kostense; P E Eysink; B C Polak; P J Beks; C Jakobs; J M Dekker; G Nijpels; R J Heine; L M Bouter; C D Stehouwer
Journal:  Arch Intern Med       Date:  2000-10-23

7.  Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin.

Authors:  T S Kern; R L Engerman
Journal:  Diabetes       Date:  2001-07       Impact factor: 9.461

8.  Lipid peroxidation and peroxynitrite in retinal ischemia-reperfusion injury.

Authors:  H Shibuki; N Katai; J Yodoi; K Uchida; N Yoshimura
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-10       Impact factor: 4.799

9.  Homocysteine levels during fasting and after methionine loading in adolescents with diabetic retinopathy and nephropathy.

Authors:  F Chiarelli; M Pomilio; A Mohn; S Tumini; M Vanelli; G Morgese; A Spagnoli; A Verrotti
Journal:  J Pediatr       Date:  2000-09       Impact factor: 4.406

10.  Serum markers of oxidative stress and severity of diabetic retinopathy.

Authors:  M E Hartnett; R D Stratton; R W Browne; B A Rosner; R J Lanham; D Armstrong
Journal:  Diabetes Care       Date:  2000-02       Impact factor: 19.112

View more
  40 in total

1.  Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy.

Authors:  Christopher H Gibbons; Roy Freeman
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

Review 2.  Challenges in elucidating the genetics of diabetic retinopathy.

Authors:  Jane Z Kuo; Tien Y Wong; Jerome I Rotter
Journal:  JAMA Ophthalmol       Date:  2014-01       Impact factor: 7.389

Review 3.  Ocular complications of diabetes mellitus.

Authors:  Nihat Sayin; Necip Kara; Gökhan Pekel
Journal:  World J Diabetes       Date:  2015-02-15

Review 4.  Neutrophil-to-lymphocyte ratio in ocular diseases: a systematic review.

Authors:  Bengi Ece Kurtul; Pinar Altiaylik Ozer
Journal:  Int J Ophthalmol       Date:  2019-12-18       Impact factor: 1.779

5.  The predictive role of markers of Inflammation and endothelial dysfunction on the course of diabetic retinopathy in type 1 diabetes.

Authors:  Hussein A Rajab; Nathaniel L Baker; Kelly J Hunt; Richard Klein; Patricia A Cleary; John Lachin; Gabriel Virella; Maria F Lopes-Virella
Journal:  J Diabetes Complications       Date:  2014-08-20       Impact factor: 2.852

6.  Systemic soluble tumor necrosis factor receptors 1 and 2 are associated with severity of diabetic retinopathy in Hispanics.

Authors:  Jane Z Kuo; Xiuqing Guo; Ronald Klein; Barbara E Klein; Jinrui Cui; Jerome I Rotter; Eli Ipp; Yii-Der Ida Chen
Journal:  Ophthalmology       Date:  2012-02-11       Impact factor: 12.079

7.  Neural inflammation and the microglial response in diabetic retinopathy.

Authors:  Steven F Abcouwer
Journal:  J Ocul Biol Dis Infor       Date:  2012-04-24

8.  Retinopathy and chronic kidney disease in the Chronic Renal Insufficiency Cohort (CRIC) study.

Authors:  Juan E Grunwald; Judith Alexander; Gui-Shuang Ying; Maureen Maguire; Ebenezer Daniel; Revell Whittock-Martin; Candace Parker; Kathleen McWilliams; Joan C Lo; Alan Go; Raymond Townsend; Crystal A Gadegbeku; James P Lash; Jeffrey C Fink; Mahboob Rahman; Harold Feldman; John W Kusek; Dawei Xie; Bernard G Jaar
Journal:  Arch Ophthalmol       Date:  2012-09

9.  Retinopathy and the risk of cardiovascular disease in patients with chronic kidney disease (from the Chronic Renal Insufficiency Cohort study).

Authors:  Juan E Grunwald; Maxwell Pistilli; Gui-Shuang Ying; Maureen Maguire; Ebenezer Daniel; Revell Whittock-Martin; Candace Parker-Ostroff; Emile Mohler; Joan C Lo; Raymond R Townsend; Crystal Ann Gadegbeku; James Phillip Lash; Jeffrey Craig Fink; Mahboob Rahman; Harold Feldman; John W Kusek; Dawei Xie
Journal:  Am J Cardiol       Date:  2015-08-31       Impact factor: 2.778

10.  C-reactive protein and diabetic retinopathy in Chinese patients with type 2 diabetes mellitus.

Authors:  Xiu-Fen Yang; Yu Deng; Hong Gu; Apiradee Lim; Torkel Snellingen; Xi-Pu Liu; Ning-Li Wang; Amitha Domalpally; Ronald Danis; Ning-Pu Liu
Journal:  Int J Ophthalmol       Date:  2016-01-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.